|
Concordia Pharmaceuticals |
|
|
612 SE 5th Avenue Suite # 3
Ft. Lauderdale, FL 33301 USA
phone:
fax:
|
|
| Symbol |
Private |
| Founded |
2003 |
| Employees |
|
|
|
| www.concordiapharma.com
|
|
|
|
 |
| Summary Description |
| Treatment of malignancies including pancreatic, lung, colon
|
|
| Management |
| Marc Watson, Chairman of the Board; Reginald Hardy, President; Victor Bauer, Ph.D., Executive Vice President; Hubert Huckel, MD, a member of the Companys Board of Directors; Mr. Watson was the co-founder and Chairman of the Board of Sano Corporation |
| |
|
|
| |
|
| Keywords |
| novel, pancreatic, lung, colon, Epidermal Growth Factor Receptor, pharmacokinetic |
|
|
|
| Description |
|
Concordia has developed a novel, orally effective, targeted well-tolerated Ras inhibitor indicated for treatment of a wide range of malignancies including pancreatic, lung, colon and other cancers. Salirasib is the first-in-class rasib and is not a farnesyltransferase inhibitor (FTI) or Epidermal Growth Factor Receptor (EGFR) antagonist. Salirasib has a much broader ability to inhibit Ras signaling by dislodging all isoforms of Ras from galectin membrane binding sites.
Clinical studies have been and are being performed at recognized Centers of Excellence, including, M.D. Anderson (safety, pharmacokinetic and food effect studies in both solid tumor and hematologic malignancies), Johns Hopkins University (a Phase I/II study dosing salirasib + gemcitabine for the treatment of newly diagnosed pancreatic cancer patients) and Memorial Sloan-Kettering (a Phase II trial treating both treatment naïve and previously treated lung cancer patients with 600mg bid salirasib mono-therapy). |
|
| Technology / Differentiation |
| Ras-inhibitors; targeting of growth signaling pathways to treat cancer. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members